Authorised COVID-19 vaccines

The table below lists the COVID-19 vaccines that are authorised for use in the EU, including originally authorised and adapted vaccines

Adapted vaccines are intended to provide broader protection against different virus variants following initial vaccination. 

Companies marketing originally authorised vaccines can apply to change the marketing authorisation to include an adapted version, which is shown in italics in the table below. 

VaccineMarketing authorisation holderKey milestones                                                                                          More information
NuvaxovidNovavax CZ, a.s.

Nuvaxovid XBB.1.5 (adapted) authorised: 31/10/2023

Standard marketing authorisation issued: 04/07/2023

Annual renewal issued: 03/10/2022

Conditional marketing authorisation issued: 20/12/2021

Latest news

Nuvaxovid: product information

Clinical data (login required)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)AstraZeneca AB

Standard marketing authorisation issued: 31/10/2022

Annual renewal issued: 09/11/2021

Conditional marketing authorisation issued: 29/01/2021

Clinical data (login required)
Spikevax (previously COVID-19 Vaccine Moderna)Moderna Biotech Spain S.L.

Spikevax XBB.1.5 (adapted) authorised: 15/09/2023

Spikevax bivalent Original/Omicron BA.4-5 (adapted) authorised: 20/10/2022

Standard marketing authorisation issued: 03/10/2022 

Spikevax bivalent Original/Omicron BA.1 (adapted) authorised: 01/09/2022

Annual renewal issued: 04/10/2021

Conditional marketing authorisation issued: 06/01/2021

Clinical data (login required)
Comirnaty (developed by BioNTech and Pfizer)BioNTech Manufacturing GmbH

Comirnaty Omicron XBB.1.5 (adapted) authorised: 31/08/2023

Standard marketing authorisation issued: 10/10/2022

Comirnaty Original/Omicron BA.4-5 (adapted) authorised: 12/09/2022

Comirnaty Original/Omicron BA.1 (adapted) authorised: 01/09/2022

Annual renewal issued: 03/11/2021

Conditional marketing authorisation issued: 21/12/2020

Clinical data (login required)
Jcovden (previously COVID-19 Vaccine Janssen)Janssen-Cilag International NV

Standard marketing authorisation issued: 10/01/2023

Annual renewal issued: 03/01/2022

Conditional marketing authorisation issued: 11/03/2021

Clinical data (login required)
Bimervax (previously COVID-19 Vaccine HIPRA) HIPRA Human Health S.L.U.Marketing authorisation issued: 30/03/2023

Latest news

Bimervax: product information

For more information on how EMA evaluated these vaccines, see:

Authorised COVID-19 treatments

The following treatments can be used in the EU to treat COVID-19:

TreatmentStatusMore information
Evusheld (tixagevimab / cilgavimab)Marketing authorisation granted: 25/03/2022Latest news
Kineret (anakinra)Marketing authorisation granted: 17/12/2021Latest news
Paxlovid (PF-07321332 / ritonavir)Conditional marketing authorisation granted: 28/01/2022

Latest news

Paediatric investigation plan

RoActemraMarketing authorisation for COVID-19 indication granted: 07/12/2021Latest news
Veklury (remdesivir)

Marketing authorisation granted: 08/08/2022

Conditional marketing authorisation granted: 03/07/2020

Latest news

Clinical data (login required)

Paediatric investigation plan

Regkirona (regdanvimab)Marketing authorisation granted: 12/11/2021

Latest news

Paediatric investigation plan

Ronapreve (casirivimab / imdevimab)Marketing authorisation granted: 12/11/2021Latest news
Xevudy (sotrovimab)Marketing authorisation granted: 17/12/2021Latest news

For more information on how EMA fast-tracks its evaluation of promising potential COVID-19 medicines, see:

COVID-19 vaccines: strains, use and age ranges

The overview below summarises the characteristics of the COVID-19 vaccines authorised in the EU:

  • Platforms - the type of technology used to develop the vaccine
  • Strains - the type of virus the vaccine targets, i.e. 'wild-type' (original), a variant or a sub-variant of the virus
  • Use - whether the vaccine is for primary or for booster vaccination
  • Population - which age groups the vaccine is used in

This overview also details the composition of COVID-19 vaccines and the milestones for authorisation of adapted vaccines.

Overview of authorised COVID-19 vaccines 

COVID-19 vaccines overview

* Available platforms: See Figure 1 below

** Milestones for adapted vaccines: See Figure 2 below

*** Only used as boosters


Figure 1: Available platforms

Available platforms for COVID-19 vaccines


Figure 2: Milestones for adapted COVID-19 vaccines

Milestones for adapted COVID-19 vaccines, from rolling review to authorisation


Safety information for authorised COVID-19 vaccines

EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any rare side effects that may emerge once many millions of people are vaccinated.

Safety information on each COVID-19 vaccine is available:

Ongoing clinical trials

Information on ongoing clinical trials for COVID-19 treatments in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):

Users can find information on:

  • phase II to phase IV adult clinical trials for COVID-19 treatments where the investigator sites are in the EEA;
  • any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.

Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.

For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see:

How useful do you find this page?